Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2024 | Story Anthony Mthembu | Photo Supplied
Melanie Ridgard
Melanie Ridgard celebrates receiving a Master of Business Administration (MBA) at the graduation ceremony held at the UFS Bloemfontein campus on 19 April 2024.

In the realm of self-development, few stories are as inspiring as that of Melanie Ridgard, the Interim Administration and Events Coordinator at the South African Research Chair in Industrial Development (SARChI-ID) at the University of Johannesburg (UJ). Ridgard’s forthcoming graduation with a Master in Business Administration (MBA) on 19 April 2024 from the University of the Free State (UFS) marks not only a personal triumph but also a testament to the transformative power of higher education.

Reflecting on her journey, Ridgard shares, “This moment signifies a culmination of rigorous studying, dedication and perseverance in mastering business fundamentals, leadership skills and strategic thinking.” Her pursuit of an MBA stemmed from a pivotal moment in her career when she was promoted at the Centre for Teaching and Learning (CTL) at UFS. Tasked with leading a group of young people Ridgard recognised the need to augment her knowledge to effectively guide her colleagues. The MBA became her vehicle for professional growth, extending beyond a mere qualification to a profound transformation of her leadership capabilities.

“Attaining an MBA milestone represents a transformative experience that has shaped my thinking to make impactful contributions in any future landscape,” Ridgard explains. Her experience not only enhanced her strategic acumen but also deepened her understanding of organisational dynamics. She acknowledges the pivotal role played by the UFS Business School in nurturing her journey towards academic and personal success.

What to expect from Ridgard

Looking ahead, Ridgard’s commitment to continuous learning remains unwavering. Selected as one of five MBA students to address the 17th International Business Conference (IBC) in September 2024, she eagerly anticipates the opportunity to share insights on her work titled, “Next-Gen Integration: Navigating the Onboarding Maze for Gen Z in Today's Workplace.” Despite her current responsibilities at UJ, she harbors plans to pursue a PhD in the near future.

Amidst her ambitious pursuits, Ridgard remains grounded, prioritising the celebration of her MBA achievement. ‘’As everyone dreams about it, I just want to walk over that stage in a black gown and a hood on my head with my loved ones cheering me on,’’ she shared.

Ridgard’s journey serves as a beacon of inspiration, exemplifying the transformative potential of education and the enduring impact of determined leadership. Her story reminds us that true leadership is not merely about reaching milestones but also about empowering others and embracing continuous growth. 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept